Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Commercial

Strategy Explore this Topic

Set Alert for Strategy

Waverley Weighs Its Options With High Costs, Thin Margins

Waverley is evaluating options for its generics as it looks likely to throw its all at the company’s lead product candidate in the hopes of luring a development partner or buyer.

Generic Drugs Strategy

Hyloris Lines Up Hectic Year Of Clinical Trials And Major US Launch

Hyloris has an eventful year ahead as it plans to conduct numerous trials for products in its ever-expanding pipeline and launch Maxigesic IV in the US.

Value-Added Medicines Clinical Trials

Eagle: ‘No Room, No Reason’ For A Generics Business, As Vasopressin Pulled

In something of a surprise, Eagle Pharmaceuticals has announced its exit from the generic vasopressin market – one year after a hard-fought and hard-won launch.

Generic Drugs Strategy
See All

Deals Explore this Topic

Set Alert for Deals

Dr Reddy’s Can Still Go It Alone After Penning Orencia Biosimilar Deal

Targeting a dual biologic for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, Coya Therapeutics has joined forces with abatacept biosimilar developer Dr Reddy’s.

Biosimilars Biologics

Rovi’s Value-Added US Risperidone Gets New Goal Date, Teva Ruled Out As Partner

Spain’s Laboratorios Farmacéuticos Rovi has a firm date to remedy issues observed in its application for a hybrid version of risperidone, developed using Rovi’s proprietary ISM drug-release technology platform.

Value-Added Medicines Complete Response Letters

Sandoz Chief Looks To Build On Recent Deals

With a number of recent deals under the firm’s belt in both generics and biosimilars, Sandoz CEO Richard Saynor talks to Generics Bulletin about how the firm is integrating new assets and building towards some key launches this year.

Deals M & A
See All

Manufacturing Explore this Topic

Set Alert for Manufacturing

Sandoz Unveils $400m+ Investment In Slovenian Biosimilars Plant

Spurred on by “increasing global demand for biosimilar medicines,” Sandoz has revealed plans to invest at least $400m in building a new biologics production plant in Slovenia.

Manufacturing Biosimilars

IHP Underlines Benefits Of Manufacturing To Donate

Global health NGO International Health Partners has set out the reasons why manufacturing to donate represents a “strategic and sustainable” way for industry partners to collaborate with the charity on relief efforts.

Manufacturing Generic Drugs

Questions Asked After Akorn’s Sudden Shutdown

Akorn is facing questions after suddenly shutting down its operations and terminating its employees, with a chapter 7 bankruptcy filing on the cards. Answers are being sought over why the company did not provide advance warnings to employees given the precarious state of its finances.

Strategy Legal Issues
See All

Sales & Earnings Explore this Topic

Set Alert for Sales & Earnings

Successful Cortrophin Gel Launch Could Drive Growth At ANI For Years To Come

The launch of ANI Pharmaceutical’s Cortrophin gel has reignited interest in the ACTH drug category, and appears set to drive growth at the company for the foreseeable future.

Sales & Earnings Rare Diseases

Amneal Continues To See Value In Complexity

With Amneal delivering what it described as a “solid” set of financials for 2022, the company has reaffirmed that it sees more value in moving increasingly into complex generics and bolstering its nascent biosimilars business.

Sales & Earnings Generic Drugs

Gloomy First Half Results For Mayne

Revenue falls 33% over the half year for the ailing Australian pharmaceutical as it pivots from generics to the branded market

Sales & Earnings Generic Drugs

People Explore this Topic

Set Alert for People

AAM Departures Lead To Change Of Chair For IGBA

The AAM has confirmed the departure of three executives, one of whom had also been serving as chair of the IGBA. As a result, the global generics industry association has brought in a new interim chair, at the same time as the head of one of the industry’s largest players has joined its CEO Advisory Committee.

Leadership Executive Changes

Who's Hired? Padagis Gets New Leadership

Former Perrigo Rx business Padagis has seen a leadership change, while Celltrion has appointed a new chief commercial officer for the US. Meanwhile, Biosimilars Canada has elected a new chair and Australia’s GBMA has welcomed fresh board members.

Executive Changes Leadership

Fresenius Pushes Kabi Even Higher As Former Sandoz Exec Named CEO

The Fresenius group spoke at length about its core Fresenius Kabi business during the company’s year-end financial call, not least its under pressure IV drugs in the US.

Sales & Earnings Strategy
See All
UsernamePublicRestriction

Register